J&J May Seek Better Deal For Guidant After ICD Recalls Lower Stock Price
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson will likely ask Guidant to lower its acquisition price by roughly $2 bil. after recent ICD recalls pushed Guidant's stock price down approximately 10%